Orthocell has today announced interim results from a new study demonstrating that Remplir™ delivers superior nerve regeneration, earlier return to function, and higher quality tissue restoration compared to current surgical suture techniques.
Read more
Orthocell has today reached another significant milestone with the successful completion of its Remplir™ 510(k) nerve repair regulatory study, validating Remplir as a safe and effective biological medical device for use in the surgical repair of peripheral nerves.
Read more
Orthocell (ASX:OCC) has announced the commencement of a nerve repair study aimed at supporting product marketing initiatives and international regulatory and reimbursement strategies for its nerve repair device, Remplir.
Read more